Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Imatinib resistance in chronic myeloid leukemia (CML) often results from BCR-ABL kinase reactivation via gene amplification or mutation.
• Targeted therapies are crucial for overcoming resistance mechanisms in CML.

Purpose of the Study:

• To investigate the efficacy of combining ponatinib (a pan-ABL tyrosine kinase inhibitor) with panobinostat (a pan-histone deacetylase inhibitor) against imatinib-resistant CML cells.
• To evaluate the synergistic effects and underlying mechanisms of this combination therapy in vitro.

Main Methods:

• Cytotoxicity assays were performed on imatinib-resistant CML cell lines (K562/IM-R1, Ba/F3/T315I) and their parental counterparts (K562, Ba/F3).
• Investigated effects on BCR-ABL phosphorylation, downstream signaling pathways, histone deacetylase activity, and apoptosis.
• Assessed the impact of ponatinib and panobinostat, alone and in combination, on cell growth and survival.

Main Results:

• Ponatinib demonstrated potent inhibition of both parental and imatinib-resistant CML cell lines.
• Panobinostat inhibited cell growth, reduced histone deacetylase activity, and induced histone H3 acetylation, suggesting disruption of HSP90 chaperone function for BCR-ABL.
• The combination of ponatinib and panobinostat exhibited synergistic growth inhibition and increased apoptosis compared to single agents, with further suppression of BCR-ABL and downstream signaling pathways.

Conclusions:

• Panobinostat significantly enhances the cytotoxic effect of ponatinib against imatinib-resistant CML cells, including those with the T315I mutation.
• The combination therapy represents a potential strategy to overcome BCR-ABL-mediated resistance in CML.
• Further investigation into this combination therapy is warranted for clinical application in CML treatment.